Song et al.347 found that the deficiency of TLR4, TLR9, and their downstream molecule MyD88 in a mouse model characterized by hepatic deletion of TAK1 could block the liver inflammation–fibrosis–cancer axis and reduce liver injury and tumor growth. The gene discussed is TLR4; the disease is cancer.